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Background
We previously reported that Adalimumab is more effica-
c i o u st h a nI n f l i x i m a bi nm aintaining remission of
chronic childhood uveitis.
Aim
To compare the efficacy of Adalimumab when used as
first anti-TNFa therapy versus Adalimumab used after
the failure of a previous anti-TNFa (Infliximab). Open-
label, comparative, multi-centre, cohort study of child-
hood non-infectious chronic uveitis.
Methods
26 patients (14 F, 12 M; median age: 8.6 years) with
refractory, vision threatening, non-infectious active uvei-
tis were enrolled. Due to the refractory course of uveitis
to previous DMARD treatment, Group 1 received Adali-
mumab (24 mg/sq mt, every 2 weeks), as first anti-
TNFa choice; Group 2 received Adalimumab, as second
anti-TNFa drug, due to the loss of efficacy of Inflixi-
mab, after a period of at least 1 year (5 mg/kg at weeks
0, 2, 6 and then every 6–8 weeks). Both groups received
Adalimumab for at least 1 year of treatment. Primary
outcome was, once remission was achieved, the time to
a first relapse. Time to achieve remission, and time to
systemic corticosteroid discontinuation were also
considered.
Results
14 children (10 with JIA, 3 with idiopathic uveitis, 1
with Behçet’s disease) were recruited in Group 1; 12
children (7 with JIA, 3 with idiopathic uveitis, 1 with
early-onset sarcoidosis, 1 with Behçet’sd i s e a s e )i n
Group 2. Cox-regression analysis did not show statistical
significant differences between the two groups with
regard to time to achieve remission, whilst Group 2
needed a longer time to discontinuation steroid (median
±SE: 7 ±1.7 vs 3 ±0.9 months, CI 95%: 3.6-10.4 vs 1.1-
4.8, p<0.001) and a lower probability to steroid disconti-
nuation during the first 12 months of treatment (Man-
tel-Cox c2 4.12, p<0.041). In long-term follow-up,
G r o u p1h a dh i g h e rp r o b a b i lity of uveitis remission
(time to first flare) than Group 2 during the time of
treatment on Adalimumab (median ±SE: 18 ±1.1 vs 4
±0.6 months, CI 95%: 15.6-27.5 vs 2.7-5.2, Mantel-Cox
c2 10.1, p<0.002) (Figure 1).
Conclusions
Even if limited to a relatively small group, our study
suggests a better efficacy of Adalimumab when used as
first anti-TNFa treatment in chronic childhood uveitis. * Correspondence: gabriele.simonini@unifi.it
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